目前没听说谁复发的,只是没有真的好假阴放回去的可能恶化,方舟子是这样解释的。我持乐观态度。除非人类真的太罪恶,上帝要让他灭亡
贴读到一个文章如下。
ADE has posed a similar challenge in the creation of vaccines for infections including dengue and a cat coronavirus, feline infectious peritonitis virus (FIPV). In one study, cats vaccinated against FIPV got sicker than cats left unvaccinated (
5). Again, the virus-specific antibody increased the virus uptake by macrophages.
Yet some experts doubt that ADE is relevant for COVID-19. “We have no evidence that ADE is actually occurring in human patients,” says Angela Rasmussen, a virologist at Columbia University Mailman School of Public Health in New York, citing such findings.
In principle, anecdotal reports of COVID-19 reinfections in China (
6) could lend credence to relevance of ADE—that is, the production of antibodies to the virus (resulting from immunization or an initial natural infection) ends up enhancing entry of the virus into cells. But Rasmussen and other experts underscore the lack of real evidence for COVID-19 reinfections. Any repeat cases so far reported, they say, could be explained by false negative tests between the positive tests. “It’s not clear that patients were ever not infected,” says Rasmussen.
And there is some preliminary experimental evidence casting doubt on ADE. Two papers published in March in
Cell show that antibodies against the original SARS infection, which emerged in China in 2002, could also block entry of SARS-CoV-2 into human cells. Another preprint study showed that rhesus macaques infected with SARS-CoV-2 and allowed to recover were not infected after a second exposure to the virus. Unless future data correlate severe COVID-19 cases with original SARS infections—or other diagnostic, pathology, or clinical findings indicate ADE—then there is “not much to go on that suggests ADE is a factor,” Rasmussen says.